Ignite Creation Date:
2024-05-05 @ 11:16 PM
Last Modification Date:
2024-10-26 @ 10:31 AM
Study NCT ID:
NCT01295112
Status:
COMPLETED
Last Update Posted:
2017-10-18
First Post:
2011-02-10
Brief Title:
Effect of Ozurdex 07 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
Sponsor:
Texas Retina Associates
Organization:
Texas Retina Associates
Study Overview
Official Title:
Effect of Ozurdex 07 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study designed to determine if the addition of Ozurdex to bevacizumab Avastin eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion
Detailed Description:
This is a multicenter clinical study designed to determine if the addition of Ozurdex injection to bevacizumab Avastin eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None